Survodutide UK: How It Works, Results & Availability

If you follow weight loss news, you've probably noticed a new name starting to appear alongside Mounjaro and Wegovy: survodutide. It's one of a handful of next-generation injections working their way through clinical trials, and the early results have caught a lot of attention. So it helps to know what survodutide actually is, what the research shows, and where it sits among the treatments you can already get today.

Here's the honest starting point. Survodutide isn't available yet. It's still being tested, and it won't be on a pharmacy shelf or a prescription pad in the UK for a while. But the science behind it matters, and understanding it helps make sense of where obesity medicine is heading.

What is survodutide?

Survodutide (you may also see it written as its research code, BI 456906) is an experimental weight loss and metabolic medication developed by Boehringer Ingelheim in partnership with Zealand Pharma. Like Wegovy and Mounjaro, it's a once-weekly injection you give yourself under the skin.

What sets it apart is how it works in the body. Most of the weight loss injections people know about act mainly on appetite. Survodutide does that too, but it adds a second mechanism aimed at how your body burns energy and stores fat, particularly in the liver. That dual action is the reason it's being studied for two conditions at once: obesity, and a serious form of fatty liver disease called MASH.

It's important to be clear about its status. Survodutide is still investigational, meaning it's in clinical trials and hasn't been approved by the MHRA, the European Medicines Agency, or the US Food and Drug Administration. You cannot legally buy it as a licensed medicine in the UK right now, and any website claiming to sell "survodutide" for weight loss should be treated with caution.

How survodutide works

Your body makes a family of hormones that help manage hunger, blood sugar and energy. Two of them matter here.

The first is GLP-1, the same hormone that Wegovy and (in part) Mounjaro work on. When you activate GLP-1 receptors, you feel fuller sooner, your stomach empties more slowly, and that constant pull towards food quietens down. Many patients describe it as the background chatter about snacks simply fading away.

The second is glucagon. This one is less familiar, and it does something different. Activating glucagon receptors is thought to nudge up the amount of energy your body uses and to encourage it to break down stored fat, including fat held in the liver. Survodutide is a dual agonist, which means it switches on both the GLP-1 and the glucagon receptors at the same time.

The idea is that you get the appetite control people already know from GLP-1 medicines, plus an extra metabolic effect on how fat is burned and stored. In theory, that combination could help with weight and with liver health together. The trials are how we find out whether the theory holds up.

What the weight loss trials show

This is where survodutide has earned its headlines, and it's also where you should look most closely, because the numbers vary depending on which study and which dose you're reading about.

The biggest and most recent result comes from SYNCHRONIZE-1, a phase 3 trial published in the New England Journal of Medicine in June 2026. It enrolled 725 adults living with obesity but without type 2 diabetes, and ran for 76 weeks. Participants were given one of two survodutide doses or a placebo. On average, people taking the higher 6.0 mg dose lost 13.0% of their body weight, compared with 5.4% for those on placebo. Up to 85.1% of people on treatment lost at least 5% of their weight, the threshold doctors usually consider clinically meaningful.

An earlier phase 2 trial had pointed to even larger figures at the highest doses tested, with average weight loss of as much as 18.7% over 46 weeks. Trials at this stage often push doses higher to see what's possible, so a gap between phase 2 and phase 3 results is normal rather than alarming. The phase 3 number is the more reliable guide to what survodutide might realistically deliver.

To put that in context, here's roughly where survodutide's headline trial result sits next to the treatments licensed in the UK today.

A note on reading tables like this: you can't compare across trials as if they were a league table. Each study recruited different people, ran for a different length, and measured weight loss in slightly different ways. What the table does show is the broad shape of things. Survodutide's phase 3 weight loss lands a little below the numbers seen with today's licensed injections, but it brings a different second mechanism, and its real distinguishing feature may turn out to be the liver.

Survodutide and fatty liver disease

The part of survodutide's story that excites many specialists isn't weight at all. It's the liver.

MASH (metabolic dysfunction-associated steatohepatitis, once called NASH) is a progressive liver condition driven by a build-up of fat that leads to inflammation and, over time, scarring. It's common in people living with obesity or insulin resistance, and until recently there were very few licensed treatments for it. That's a real gap in care, because advanced MASH can lead to cirrhosis and liver failure.

Survodutide's glucagon action is thought to work directly on the liver, which is why it's being tested here. In a 48-week phase 2 trial of 293 adults with biopsy-confirmed MASH and fibrosis, 62% of people on the 4.8 mg dose saw their MASH improve without their fibrosis getting worse, compared with just 14% on placebo. Liver fat also fell by at least 30% in around two-thirds of those treated.

For someone carrying extra weight who also has a fatty liver, a single treatment that could help with both is a meaningful prospect. But these are phase 2 liver results, and the larger phase 3 programme is what will tell us whether the effect is durable and safe over the long run.

How survodutide compares to Mounjaro, Wegovy and retatrutide

People often ask which of these medicines is "best". It's the wrong question at this stage, partly because survodutide isn't available and partly because the honest answer is: it depends on the person.

Wegovy and Mounjaro are here now, licensed, and backed by years of real-world use. If you're eligible and looking for treatment today, those are the options a clinician can actually prescribe. You can read more about them in our guide to weight loss medication in the UK and our breakdown of how GLP-1 medicines work.

Survodutide and retatrutide are further back in the queue. Both are experimental, and both take the "target more than one receptor" idea in different directions. Survodutide adds glucagon to GLP-1. Retatrutide, sometimes nicknamed the "triple G", adds both GIP and glucagon, and its phase 2 weight loss figures have been the highest of any of these drugs so far. If you want the fuller picture on that one, we've covered retatrutide in the UK separately, along with the first weight loss pill on the horizon, orforglipron.

The takeaway isn't that one wins. It's that the field is widening. A few years ago there was essentially one type of injection. Soon there may be several, each with a slightly different mechanism, which means more chances to match a treatment to the person in front of you.

Side effects: what the trials report

Survodutide's side effect profile looks broadly similar to other medicines in this family, which makes sense given the shared GLP-1 mechanism.

The most common issues reported in trials were gastrointestinal: nausea, vomiting, diarrhoea and constipation. These tended to appear during the dose-escalation phase, when the dose is being gradually increased, and were mostly mild to moderate. This is exactly why these medicines are started low and titrated up slowly, giving your body time to adjust. Rushing the dose is what tends to make people feel rough.

Because survodutide also acts on glucagon, researchers are watching its effects on heart rate and blood sugar carefully, as glucagon can influence both. That's part of what the larger phase 3 trials are designed to pin down. Until that long-term safety data is complete and reviewed by regulators, nobody can say the full picture with certainty, and it would be wrong to pretend otherwise.

When will survodutide be available in the UK?

The short answer is: not soon, and not certainly.

Survodutide is in phase 3, the final and largest stage of testing before a company can apply for approval. That programme has to finish, the full results have to be reviewed, and then Boehringer Ingelheim would need to submit the drug to regulators like the MHRA. Even in an optimistic scenario, UK availability wouldn't come before 2027, and only if the trials continue to look strong and regulators agree.

There's a further step for NHS access. Even after a medicine is licensed, the National Institute for Health and Care Excellence (NICE) assesses whether it should be funded on the NHS and for whom. That process takes time, as anyone who followed the slow, staged NHS rollout of Wegovy and Mounjaro will remember. In practice, if survodutide is approved, it would most likely be offered through private providers first, with any NHS route following later.

So survodutide is one to watch, not one to wait for. If you're ready to do something about your weight now, holding out for a drug that's still years from the market usually isn't the kindest choice you can make for yourself.

What you can do now

If reading about survodutide has you thinking about treatment, you don't have to wait for it. Two effective GLP-1 medicines, Wegovy and Mounjaro, are already licensed in the UK and available through regulated providers, alongside the lifestyle support that makes any of these treatments work better.

The most important step isn't choosing a specific drug. It's a proper medical assessment: someone looking at your health, your history and your goals, and helping you decide whether treatment is appropriate and, if so, which one. If cost is on your mind, our guide to Wegovy prices in the UK lays out what you'd actually pay. And if a treatment isn't right for you at all, a good clinician will tell you that too.

This article is for informational purposes only and does not constitute medical advice. Always consult with a qualified healthcare professional before starting any treatment.